Market Research Logo

The Global Market for Pain Management Drugs and Devices

The Global Market for Pain Management Drugs and Devices

Market for global pain management pharmaceuticals and devices by revenue at manufacturers’ sales levels is projected to grow from $36.6 billion in 2014 to nearly $37.8 billion in 2015 and $44.3 billion in 2020, with a compound annual growth rate (CAGR) of 3.2% between 2015 and 2020.

This report provides:
An overview of the global market for pain management drugs, which will address acute vs. chronic pain, treatments, and issues facing healthcare workers.
Analyses of global market trends, with data from 2013 and 2014; estimates for 2015, and projections of CAGRs through 2020.
Examination of product categories, use of products, and the competitive landscape.
Coverage of several significant market trends, including undertreatment issues, professional issues, managed care pain issues, trends in new therapies, product pipelines, generic participation, pain research, drug delivery, and patent expirations.
Discussion of new regulatory requirements.
Comprehensive company profiles of major players in the industry.


SCOPE AND FORMAT

This BCC Research report is designed to be a helpful business tool that will provide a thorough evaluation of the markets for pain management. The geographical scope of this study is global. This study will address acute versus chronic pain, treatments and regulatory issues facing healthcare workers. Also provided is detailed information based on product categories, use of products, forecasts and competitive analyses.

The report identifies two general segments of pain management:
Pharmaceuticals
Devices.

Within the pharmaceuticals segment several sub-segments are discussed in detail, including:
Narcotic pain management.
Non-narcotic pain management.
Antimigraine treatments.
Anesthetics.
Other drugs (including fibromyalgia treatments).

The device segment covers several product lines and specifically targets the largest product segments including:
Electrotherapy stimulators.
Spine stimulators.
Other products (including electromagnetic therapies and other treatments).

For each market segment detailed information is provided based on product categories, product use, forecasts and competitive analyses.

CHAPTER 1 INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY AND INTENDED AUDIENCE
SCOPE AND FORMAT
METHODOLOGY AND SOURCES OF INFORMATION
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 SUMMARY
OVERVIEW
GENERAL PAIN TERMINOLOGY
MAJOR MARKETS SUMMARY
SUMMARY TABLE MARKET FOR GLOBAL PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REVENUE AT MANUFACTURERS’ SALES LEVELS, THROUGH 2020 ($ MILLIONS)
SUMMARY FIGURE MARKET FOR GLOBAL PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REVENUE AT MANUFACTURERS’ SALES LEVELS, 2012-2020 ($ MILLIONS)
MARKET TRENDS
UNDERTREATMENT ISSUES
PROFESSIONAL PAIN TREATMENT ISSUES
ACCESS TO CARE
FDA APPROVAL REQUIREMENTS FOR PAIN THERAPIES
DRUG DELIVERY SYSTEMS
CHAPTER 3 INDUSTRY OVERVIEW
HISTORY OF PAIN AND PAIN TREATMENT
THE PERCEPTION OF PAIN
Types of Pain
Acute Pain
Chronic Pain
ASSESSMENT OF PAIN
Subjective
Objective
TABLE 1 OBJECTIVE SIGNS OF PAIN
HOW PAIN IS DIAGNOSED
HOW PAIN IS TREATED
FIGURE 1 PAIN-MANAGEMENT TECHNIQUES
DEMOGRAPHICS AND AGING POPULATIONS
Global Demographic Overview
TABLE 2 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS)
FIGURE 2 GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND 2015 (MILLIONS)
The Aging Population
TABLE 3 ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS)
FIGURE 3 ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 (MILLIONS)
Global Life Expectancy
TABLE 4 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980-2015 (YEARS)
FIGURE 4 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED
COUNTRY, 1980-2015 (YEARS)
THE NEED FOR PAIN MANAGEMENT
Developments in Treating Neuropathic Pain
MIGRAINE HEADACHE PAIN MANAGEMENT
CANCER PAIN MANAGEMENT
Pain Management in Cancer
FIGURE 5 CAUSES OF CANCER PAIN
TABLE 5 CANCER PAIN MEDICATIONS
Developments in Breakthrough Cancer Pain
ORTHOPEDIC PAIN MANAGEMENT
Osteoarthritis
Rheumatoid Arthritis
Ankylosing Spondylitis
Fibromyalgia
Gout
Scleroderma
Lupus
Bursitis and Tendonitis
TABLE 6 ESTIMATED* PREVALENCE/INCIDENCE OF ORTHOPEDIC CONDITIONS BY COUNTRY, AVERAGE FIGURE, 2010-2013 (MILLIONS)
FIGURE 6 ESTIMATED* PREVALENCE/INCIDENCE OF ORTHOPEDIC CONDITIONS BY COUNTRY, AVERAGE FIGURE 2010-2013 (MILLIONS)
HIV/AIDS RELATED PAIN
BURN PAIN
Stages of Burn Healing
Challenges Associated with Burn Pain
Burn Pain Management
FIGURE 7 APPROACH TO BURN PAIN MANAGEMENT
DENTAL PAIN
Treatment for Dental Pain
OBSTETRICS PAIN
TABLE 7 BIRTH RATES AND BIRTHS BY COUNTRY, 2015 (THOUSANDS)
FIGURE 8 BIRTH RATES AND BIRTHS BY COUNTRY, 2015 (THOUSANDS)
SURGICAL PAIN
GENDER AND PAIN
TABLE 8 PEOPLE WHO REPORTED PAIN BY SELECTED CATEGORY AND GENDER IN THE 18+ U.S. POPULATION*, 1997-2010 (THOUSANDS)
OTHER INFLUENCES DETERMINING HOW PAIN IS FELT AMONG INDIVIDUALS
Objective Pain Measurement
PEDIATRIC PAIN
CHAPTER 4 INDUSTRY TRENDS
OVERVIEW
UNDERTREATMENT ISSUES
PAIN IN OLDER PATIENTS
PAIN IN YOUNGER PATIENTS
TREATMENT OF PAIN AND ISSUES FACING THE PROFESSIONAL SEGMENT
TABLE 9 AVAILABILITY OF EDUCATION IN PAIN MANAGEMENT BY SELECT
REGION/COUNTRY
PRESCRIPTION DRUG MONITORING PROGRAMS
TABLE 10 NUMBER OF AGENCIES RESPONSIBLE FOR PDMP IN EACH STATE, BY TYPE
TABLE 11 BENEFITS OF PRESCRIPTION MONITORING PROGRAMS FOR MEDICAL BOARDS
TABLE 12 DRUGS MONITORED BY PDMPS
TABLE 13 STATES WITH ELECTRONIC PRESCRIPTION MONITORING
PROGRAMS
FIGURE 9 NUMBER OF STATES WITH ELECTRONIC PRESCRIPTION MONITORING PROGRAMS BY YEAR OF ENACTMENT
TABLE 14 NURSE CONTINUING EDUCATION REQUIREMENTS FOR PAIN MANAGEMENT BY REQUIRING STATE
ACCESS TO CARE
ACCESS TO PALLIATIVE CARE
Assessing the Need for Palliative Care
FIGURE 10 NUMBER OF DEATHS, BY CAUSES OF MORTALITY AND POTENTIAL NEED FOR PALLIATIVE CARE (MILLIONS)
AVAILABILITY OF MEDICATIONS
TABLE 15 WHO ESSENTIAL MEDICINES LIST (ADULTS) FOR PAIN MANAGEMENT
TABLE 16 AVAILABILITY OF INJECTABLE MORPHINE BY REGION
TABLE 17 AVAILABILITY OF ORAL MORPHINE IN HOSPICE-TYPE SETTINGS, BY REGION
International Narcotics Control Board and Obstacles to Availability
FIGURE 11 FACTORS AFFECTING AVAILABILITY OF OPIOIDS FOR MEDICAL NEEDS, 2010
GOVERNMENT INTERVENTION
Drug Supply
FDA Drug Shortages for Pain Therapies
TABLE 18 FDA ANALGESIA DRUG SHORTAGES BY REPORTING
COMPANY, JULY 2015
Single Convention on Narcotic Drugs
Government Subsidies
PREVENTING OPIOID-INDUCED CONSTIPATION AND REDUCED COMPLIANCE
PUBLIC HEALTHCARE SYSTEMS AROUND THE WORLD
TABLE 19 WORLD HEALTH ORGANIZATION TOP 50 RANKING OF HEALTHCARE SYSTEMS, 2000
RISING HEALTHCARE COSTS
TABLE 20 HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY COUNTRY, 1980-2015 (%)
FIGURE 12 HEALTH EXPENDITURES AS PERCENT OF GDP BY COUNTRY, 1980-2015 (%)
AVERAGE LENGTH OF STAY
MANAGED CARE PAIN MANAGEMENT ISSUES
FDA APPROVAL REQUIREMENTS FOR PAIN THERAPIES
FDA APPROVAL REQUIREMENTS FOR PAIN DEVICES
510(K) EXEMPTIONS
TABLE 21 PARTS 862-892 OF 21 CFR
RISK EVALUATION AND MITIGATION STRATEGY (REMS)
TABLE 22 LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID BRAND-NAME PRODUCTS REQUIRED TO HAVE AN OPIOID REMS, MAY 2015
TABLE 23 LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID GENERIC PRODUCTS REQUIRED TO HAVE AN OPIOID REMS, MAY 2015
TABLE 24 TRANSMUCOSAL IMMEDIATE-RELEASE FENTANYL PRODUCTS
REQUIRED TO HAVE TIRF REMS ACCESS PROGRAM
ACETAMINOPHEN AND FDA CHANGES
TABLE 25 MARKETED ACETAMINOPHEN-CONTAINING PRESCRIPTION
PRODUCTS
CODEINE IN COUGH AND COLD MEDICATIONS
NON-ASPIRIN NSAIDS LINKED TO INCREASED RISK OF HEART ATTACK OR STROKE
TABLE 26 NON-ASPIRIN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
DRUG DELIVERY SYSTEMS
ORAL AND EXTENDED RELEASE
TOPICAL AND TRANSDERMAL
INTRAVENOUS
INTRANASAL
PATIENT-CONTROLLED ANALGESIA
IONTOPHORESIS
TABLE 27 ADVANTAGES AND DISADVANTAGES OF IONTOPHORETIC
DRUG DELIVERY
ELECTROMECHANICAL TRANSPORT
CHAPTER 5 TREATING PAIN
OVERVIEW
PHARMACEUTICAL PAIN MANAGEMENT
PRESCRIPTION PAIN MANAGEMENT PRODUCTS
TABLE 28 RECENT FDA APPLICATIONS/APPROVALS, JANUARY 2010-JULY
2015
Analgesic Drugs
Non-Narcotics
Narcotics
Full and Partial Agonists
Agonist-Antagonists
Nonsteroid Anti-inflammatory Drugs
Antimigraine Drugs
Antidepressant, Anticonvulsants and Other Pain Relieving Drugs
Anesthetics
General Anesthesia
TABLE 29 MOST COMMONLY USED GENERAL ANESTHETIC AGENTS
Local/Regional
Topical
OVER-THE-COUNTER PAIN MANAGEMENT PRODUCTS: OVERVIEW
ANALGESIC DRUGS
TABLE 30 OTC ACETAMINOPHEN AND ACETAMINOPHEN COMBINATION
PRODUCTS
NONSTEROID ANTI-INFLAMMATORY DRUGS
Aspirin Products and Aspirin Combination Products
TABLE 31 OTC ASPIRIN AND ASPIRIN COMBINATION PRODUCTS
Ibuprofen and Ibuprofen Combination Products
TABLE 32 OTC IBUPROFEN AND IBUPROFEN COMBINATION
PRODUCTS
Ketoprofen Products
TABLE 33 OTC KETOPROFEN PRODUCTS
Naproxen Compounds
TABLE 34 OTC NONSTEROID ANTI-INFLAMMATORIES
ANTIMIGRAINE DRUGS
TABLE 35 OTC ANTIMIGRAINE PRODUCTS
TOPICAL ANESTHETIC DRUGS
TABLE 36 OTC TOPICAL ANESTHETIC PRODUCTS
PAIN MANAGEMENT DEVICES
STIMULATION THERAPY
Electrotherapy
Neuromuscular Stimulators
Pain TEM
Spine Stimulation
COMBINATION PAIN MANAGEMENT DEVICES
LASER DEVICES
ELECTROMAGNETIC THERAPY DEVICES
INTRATHECAL DEVICES
OTHER PAIN DEVICES AND METHODS
PAIN MANAGEMENT PROCEDURES: STEROIDS, ENDOSCOPY AND FLUOROSCOPY
ALTERNATIVE METHODS OF PAIN MANAGEMENT
PHYSICAL PAIN TREATMENT MODALITIES
Acupuncture/Acupressure
Ice (Cryotherapy)
Joint Mobilization
Manipulation
Massage
Traction
Radiation Therapy
Radio Frequency Neuroablation, Epiduroscopy
Surgery
Whirlpool Bath (Thermotherapy)
PSYCHOLOGICAL PAIN THERAPIES
Biofeedback
Hypnosis
Behavior Modification/Operant Conditioning
Relaxation and Stress Management Training
Imagery
Autogenic Training
Psychosocial Interventions
Distraction and Reframing
TRACKING THE DEVELOPMENT OF COMPLEMENTARY AND ALTERNATIVE
PAIN CONTROL METHODS
TABLE 37 ADULTS 18 YEARS AND OVER IN THE U.S. WHO USED COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY THERAPY TYPE, 2002-2015 (THOUSANDS)
FIGURE 13 ADULTS 18 YEARS AND OVER IN THE U.S. WHO USED COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY THERAPY TYPE, 2002-2015 (THOUSANDS)
PAIN MANAGEMENT SERVICES AND ORGANIZATIONS
HOME CARE
HOSPICE
FIGURE 14 NUMBER OF HOSPICE PATIENTS SERVED BY YEAR, 2009–2013
TABLE 38 STATISTICS FOR HOSPICE PATIENTS BY CHARACTERISTIC,
2009-2013 (%)
FIGURE 15 PERCENTAGE OF HOSPICE PATIENTS BY GENDER, 2009-2013 (%)
FIGURE 16 PERCENTAGE OF HOSPICE PATIENTS BY AGE GROUP, 2009-2013 (%)
TABLE 39 STATISTICS OF HOSPICE PATIENTS BY PRIMARY DIAGNOSIS (THOUSAND/%)
FIGURE 17 PERCENTAGE OF HOSPICE PATIENTS BY PRIMARY DIAGNOSIS, 2009-2013 (%)
NATIONAL HOSPICE AND PALLIATIVE CARE ORGANIZATION
TABLE 40 NHPCO COMMITTEES
HOSPITALS
TABLE 41 NUMBER OF REGISTERED HOSPITALS BY COUNTRY, 2010
TABLE 42 NUMBER OF REGISTERED U.S. HOSPITALS BY TYPE, 2013
Hospital Departments
Emergency Rooms
Critical Care Units
PAIN CLINICS
TABLE 43 NUMBER OF REGISTERED PAIN CLINICS IN THE U.S. BY STATE, 2015
TABLE 44 NUMBER OF REGISTERED PAIN CLINICS, BY COUNTRY
SKILLED NURSING FACILITIES
CHAPTER 6 PHARMACEUTICAL PAIN MANAGEMENT MARKET SIZE AND ANALYSIS
TOTAL MARKET
PRESCRIPTION PAIN MARKETS BY PRODUCT TYPE
TABLE 45 MARKET FOR GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS AT MANUFACTURERS’ SALES LEVELS BY CATEGORY, THROUGH 2020 ($ MILLIONS)
FIGURE 18 MARKET FOR GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS AT MANUFACTURERS’ SALES LEVELS BY CATEGORY, 2012-2020 ($ MILLIONS)
NARCOTIC ANALGESICS
TABLE 46 GLOBAL MARKET FOR NARCOTIC ANALGESICS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 19 GLOBAL MARKET FOR NARCOTIC ANALGESICS BY REGION, 2012-2020 ($ MILLIONS)
NON-NARCOTIC ANALGESICS
TABLE 47 GLOBAL MARKET FOR NON-NARCOTIC ANALGESICS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 20 GLOBAL MARKET FOR NON-NARCOTIC ANALGESICS BY REGION, 2012-2020 ($ MILLIONS)
ANTIMIGRAINE AGENTS
TABLE 48 GLOBAL MARKET FOR ANTIMIGRAINE AGENTS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 21 GLOBAL MARKET FOR ANTIMIGRAINE AGENTS BY REGION, 2012-2020 ($ MILLIONS)
ANESTHETICS
TABLE 49 GLOBAL MARKET FOR ANESTHETICS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 22 GLOBAL MARKET FOR ANESTHETICS BY REGION, 2012-2020 ($ MILLIONS)
OTHER DRUG CLASSES
TABLE 50 GLOBAL MARKET FOR OTHER CNS ANALGESICS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 23 GLOBAL MARKET FOR OTHER CNS ANALGESICS BY REGION, 2012-2020 ($ MILLIONS)
MARKET PARTICIPANTS
NARCOTIC/NON-NARCOTIC MARKET SHARE
TABLE 51 GLOBAL MARKET FOR PRESCRIPTION NARCOTIC AND NON-NARCOTIC BY MANUFACTURER, 2015 ($ MILLIONS/%)
FIGURE 24 GLOBAL MARKET FOR PRESCRIPTION NARCOTIC AND NON-NARCOTIC BY MANUFACTURER, 2015 ($ MILLIONS)
MIGRAINE TREATMENT MARKET SHARE
TABLE 52 GLOBAL MARKET FOR PRESCRIPTION ANTIMIGRAINE DRUG BY MANUFACTURER, 2015 ($ MILLIONS/%)
FIGURE 25 GLOBAL MARKET FOR PRESCRIPTION ANTIMIGRAINE DRUG BY MANUFACTURER, 2015 (%)
ANESTHETIC MARKET SHARE
TABLE 53 GLOBAL MARKET FOR PRESCRIPTION ANESTHETIC BY MANUFACTURER, 2015 ($ MILLIONS/%)
FIGURE 26 GLOBAL MARKET FOR PRESCRIPTION ANESTHETIC BY MANUFACTURER, 2015 (%)
FUTURE MARKET ANALYSIS
CHAPTER 7 PAIN MANAGEMENT DEVICE MARKET SIZE AND ANALYSIS
INTRODUCTION
TOTAL PAIN MANAGEMENT DEVICE MARKET
FIGURE 27 GLOBAL PAIN MANAGEMENT DEVICE MARKET AT MANUFACTURERS’ SALES LEVELS, 2012-2020 ($ MILLIONS)
PAIN MARKETS BY PRODUCT TYPE
ELECTROTHERAPY
SPINE STIMULATORS
OTHER PAIN TREATMENT DEVICES
TABLE 54 GLOBAL PAIN MANAGEMENT DEVICE MARKET AT MANUFACTURERS’ SALES LEVELS BY PRODUCT TYPE, THROUGH 2020 ($ MILLIONS)
FIGURE 28 GLOBAL PAIN MANAGEMENT DEVICE MARKET BY PRODUCT TYPE, 2012-2020 ($ MILLIONS)
TABLE 55 GLOBAL MARKET FOR PAIN MANAGEMENT DEVICES BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 29 GLOBAL MARKET FOR PAIN MANAGEMENT DEVICES BY REGION, 2012-2020 ($ MILLIONS)
MARKET PARTICIPANTS
TABLE 56 GLOBAL MARKET FOR NEUROMUSCULAR STIMULATOR/ELECTROTHERAPY DEVICES BY MANUFACTURER, 2015 ($ MILLIONS/%)
FIGURE 30 GLOBAL MARKET SHARE FOR NEUROMUSCULAR STIMULATOR/ELECTROTHERAPY DEVICES BY MANUFACTURER, 2015 (%)
TABLE 57 GLOBAL MARKET FOR SPINE STIMULATORS BY MANUFACTURER, 2015 ($ MILLIONS/%)
FIGURE 31 GLOBAL MARKET SHARE FOR SPINE CORD STIMULATORS BY MANUFACTURER, 2015 (%)
FUTURE MARKET ANALYSIS
CHAPTER 8 TOTAL MARKET SUMMARY
TOTAL PAIN MANAGEMENT MARKET
TABLE 58 GLOBAL MARKET FOR PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REVENUE AT MANUFACTURERS’ SALES LEVELS, THROUGH 2020 ($ MILLIONS)
FIGURE 32 GLOBAL MARKET FOR PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REVENUE AT MANUFACTURERS’ SALES LEVELS, 2012-2020 ($ MILLIONS)
MARKET PERCENTAGE BY PRODUCT TYPE
TABLE 59 GLOBAL PAIN MANAGEMENT MARKET BY SEGMENT, 2015 ($ MILLIONS/%)
FIGURE 33 GLOBAL PAIN MANAGEMENT MARKET SHARE BY SEGMENT, 2015 (%)
MARKETS BY GLOBAL REGION
TABLE 60 GLOBAL MARKET FOR PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 34 GLOBAL MARKET FOR PAIN MANAGEMENT DEVICES BY REGION, 2012-2020 ($ MILLIONS)
CHAPTER 9 INDUSTRY DEVELOPMENTS
TIMELINE OF RECENT EVENTS AND DEVELOPMENTS
THE PHARMACEUTICAL PIPELINE
TABLE 61 MANUFACTURERS’ PAIN-MANAGEMENT DRUG PIPELINES
FIGURE 35 PAIN MANAGEMENT DRUG PIPELINE, BY DEVELOPMENT STATUS
FIGURE 36 PAIN MANAGEMENT DRUG PIPELINE, BY PRIMARY INDICATION
PATENT ANALYSIS
NUMBER OF PATENTS ISSUED FOR PAIN
TABLE 62 NUMBER OF PAIN FOCUS PATENTS ISSUED, BY ABSTRACT
DESCRIPTION
TABLE 63 NUMBER OF U.S. PATENTS FOR PAIN-FOCUSED INVENTIONS BY YEAR, JANUARY 2000-JULY 2015
FIGURE 37 NUMBER OF U.S. PATENTS FOR PAIN-FOCUSED INVENTIONS BY YEAR, JANUARY 2000-JULY 2015
DRUG PATENTS FOR SELECTED THERAPIES
TABLE 64 U.S. PATENT EXPIRATION DATES FOR SELECTED PAIN DRUGS IMPACT OF GENERIC PARTICIPATION
TABLE 65 FIRST-TIME PRESCRIPTION GENERIC PAIN MANAGEMENT AND APPROVALS, APRIL 2005-JULY 2015
PAIN DEVICE CLINICAL TRIALS
TABLE 66 SELECTED PAIN MANAGEMENT DEVICE TRIALS
FIGURE 38 NUMBER OF PAIN MANAGEMENT DEVICES IN DEVELOPMENT, BY GENERAL STATUS
FUTURE OF PAIN RESEARCH
TABLE 67 PAIN OR PAIN-RELATED CLINICAL TRIALS, BY REGION, 2015
FIGURE 39 PERCENTAGE OF PAIN-FOCUSED CLINICAL TRIALS FOR ALL AGES, BY REGION (%)
PAIN RESEARCH - PEDIATRIC POPULATIONS
FIGURE 40 PERCENTAGE OF PAIN-FOCUSED CLINICAL TRIALS FOR PEDIATRICS, BY REGION (%)
PATIENT OUTCOMES RESEARCH
SELECTED PAIN-RELATED ACQUISITIONS AND ALLIANCES
CHAPTER 10 COMPANY PROFILES
PHARMACEUTICAL AND DEVICE PAIN MANAGEMENT MANUFACTURERS
ABBVIE INC.
ASTRAZENECA
DEPOMED INC.
DJO GLOBAL INC.
ELI LILLY & CO.
ENDO INTERNATIONAL
GLAXOSMITHKLINE
HISAMITSU PHARMACEUTICAL CO. INC.
JOHNSON & JOHNSON
MEDTRONIC INC.
NOVARTIS INTERNATIONAL AG
PFIZER
PURDUE PHARMACEUTICALS LP
ST. JUDE MEDICAL INC.
CHAPTER 11 APPENDIX I
PAIN MANAGEMENT PHARMACEUTICAL MANUFACTURERS AND DEVELOPERS
CHAPTER 12 APPENDIX II
2015-2016 STATE CONTROLLED SUBSTANCES SCHEDULING AUTHORITIES AND OTHER HELPFUL CONTACT PERSONS
ALABAMA
ALASKA
ARIZONA
ARKANSAS
CALIFORNIA
COLORADO
CONNECTICUT
DELAWARE
DISTRICT OF COLUMBIA
FLORIDA
GEORGIA
HAWAII
IDAHO
ILLINOIS
INDIANA
IOWA
KANSAS
KENTUCKY
LOUISIANA
MAINE
MARYLAND
MASSACHUSETTS
MICHIGAN
MINNESOTA
MISSISSIPPI
MISSOURI
MONTANA
NEBRASKA
NEVADA
NEW HAMPSHIRE
NEW JERSEY
NEW MEXICO
NEW YORK
NORTH CAROLINA
NORTH DAKOTA
OHIO
OKLAHOMA
OREGON
PENNSYLVANIA
RHODE ISLAND
SOUTH CAROLINA
SOUTH DAKOTA
TENNESSEE
TEXAS
UTAH
VERMONT
VIRGINIA
WASHINGTON
WEST VIRGINIA
WISCONSIN
WYOMING
CHAPTER 13 APPENDIX III
U.S. PAIN SOCIETIES AND ASSOCIATIONS
CHAPTER 14 APPENDIX IV
INTERNATIONAL ASSOCIATIONS AND ORGANIZATIONS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report